3 Out-of-Favor Stocks We Keep Off Our Radar

Hitting a new 52-week low can be a pivotal moment for any stock. These floors often mark either the beginning of a turnaround story or confirmation that a company faces serious headwinds.

At StockStory, we dig beneath the surface of price movements to uncover whether a company's fundamentals justify its current valuation or suggest hidden potential. That said, here are three stocks facing legitimate challenges and some alternatives worth exploring instead.

Commerce (CMRC)

One-Month Return: -19.4%

As a founding member of the MACH Alliance advocating for modern tech standards, Commerce (NASDAQ:CMRC) provides a SaaS platform that enables businesses to build and manage online stores, connect with marketplaces, and integrate with point-of-sale systems.

Why Do We Think CMRC Will Underperform?

1. Average billings growth of 2.4% over the last year was subpar, suggesting it struggled to push its software and might have to lower prices to stimulate demand
2. Estimated sales growth of 4.1% for the next 12 months implies demand will slow from its two-year trend
3. Low free cash flow margin of 8.3% for the last year gives it little breathing room, constraining its ability to self-fund growth or return capital to shareholders

Commerce’s stock price of $3.40 implies a valuation ratio of 0.9x forward price-to-sales. Check out our free in-depth research report to learn more about why CMRC doesn’t pass our bar.

Domo (DOMO)

One-Month Return: -37.4%

Named for the Japanese word meaning "thank you very much," Domo (NASDAQ:DOMO) provides a cloud-based business intelligence platform that connects people with real-time data and insights across organizations.

Why Do We Avoid DOMO?

1. Billings didn’t grow over the last year, suggesting the company struggled to sell its software and might have to lower prices to stimulate growth
2. Demand will likely be soft over the next 12 months as Wall Street’s estimates imply tepid growth of 1.2%
3. Customer acquisition costs take a while to recoup, making it difficult to justify sales and marketing investments that could increase revenue

Domo is trading at $5.76 per share, or 0.8x forward price-to-sales. If you’re considering DOMO for your portfolio, see our FREE research report to learn more.

Enovis (ENOV)

One-Month Return: -15%

With a focus on helping patients regain or maintain their natural motion, Enovis (NYSE:ENOV) develops and manufactures medical devices for orthopedic care, from injury prevention and pain management to joint replacement and rehabilitation.

Why Are We Out on ENOV?

1. Products and services are facing significant end-market challenges during this cycle as sales have declined by 6.5% annually over the last five years
2. Negative returns on capital show that some of its growth strategies have backfired, and its decreasing returns suggest its historical profit centers are aging
3. Shrinking returns on capital from an already weak position reveal that neither previous nor ongoing investments are yielding the desired results

At $23.13 per share, Enovis trades at 7.4x forward P/E. To fully understand why you should be careful with ENOV, check out our full research report (it’s free).

Stocks We Like More

If your portfolio success hinges on just 4 stocks, your wealth is built on fragile ground. You have a small window to secure high-quality assets before the market widens and these prices disappear.

Don’t wait for the next volatility shock. Check out our Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 244% over the last five years (as of June 30, 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.